These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2541742)

  • 1. Consequences of angiotensin-converting enzyme inhibitor overdose.
    Varughese A; Taylor AA; Nelson EB
    Am J Hypertens; 1989 May; 2(5 Pt 1):355-7. PubMed ID: 2541742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
    Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
    J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment.
    Lees KR; Reid JL
    Clin Pharmacol Ther; 1987 Jun; 41(6):597-602. PubMed ID: 3034468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Ajayi AA; Hockings N; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):349-57. PubMed ID: 3011047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of angiotensin converting enzyme (ACE) in the pharmacokinetics and pharmacodynamics of ACE inhibitors.
    Johnston CI; Jackson B; Cubela R; Larmour I; Arnolda L
    J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S9-14. PubMed ID: 2422495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.
    Johnston CI; Jackson B; McGrath B; Matthews G; Arnolda L
    J Hypertens Suppl; 1983 Oct; 1(1):71-5. PubMed ID: 6100611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
    Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
    Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics and dynamics of enalapril in patients with liver cirrhosis.
    Ohnishi A; Tsuboi Y; Ishizaki T; Kubota K; Ohno T; Yoshida H; Kanezaki A; Tanaka T
    Clin Pharmacol Ther; 1989 Jun; 45(6):657-65. PubMed ID: 2543535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses.
    Gómez-Díez M; Muñoz A; Caballero JM; Riber C; Castejón F; Serrano-Rodríguez JM
    Res Vet Sci; 2014 Aug; 97(1):105-10. PubMed ID: 24972864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.
    Reams GP; Lal SM; Whalen JJ; Bauer JH
    J Clin Hypertens; 1986 Sep; 2(3):245-53. PubMed ID: 3023555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
    MacFadyen RJ; Lees KR; Reid JL
    Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of zinc depletion on angiotensin I-converting enzyme in arterial walls and plasma of the rat.
    Dahlheim H; White CL; Rothemund J; von Lutterotti N; Jacob IC; Rosenthal J
    Miner Electrolyte Metab; 1989; 15(3):125-9. PubMed ID: 2542744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis.
    Matalka K; Arafat T; Hamad M; Jehanli A
    Fundam Clin Pharmacol; 2002 Jun; 16(3):237-44. PubMed ID: 12165071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compared properties of trandolapril, enalapril, and their diacid metabolites.
    Chevillard C; Jouquey S; Bree F; Mathieu MN; Stepniewski JP; Tillement JP; Hamon G; Corvol P
    J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S11-5. PubMed ID: 7527095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum enalaprilat in chronic renal failure.
    Elung-Jensen T; Heisterberg J; Kamper AL; Sonne J; Strandgaard S; Larsen NE
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):240-5. PubMed ID: 11881130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers.
    Zapater P; Novalbos J; Gallego-Sandín S; Hernández FT; Abad-Santos F
    J Cardiovasc Pharmacol; 2004 May; 43(5):737-44. PubMed ID: 15071363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure.
    MacFadyen RJ; Lees KR; Reid JL
    Br Heart J; 1993 Apr; 69(4):293-7. PubMed ID: 8387806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?
    van den Meiracker AH; Man in 't Veld AJ; Admiraal PJ; Ritsema van Eck HJ; Boomsma F; Derkx FH; Schalekamp MA
    J Hypertens; 1992 Aug; 10(8):803-12. PubMed ID: 1325513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-performance liquid chromatographic determination of enalapril in human plasma by enzyme kinetic analytical method.
    Thongnopnua P; Poeaknapo C
    J Pharm Biomed Anal; 2005 Apr; 37(4):763-9. PubMed ID: 15797799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.